



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO.  | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-------------|----------------------|---------------------|------------------|
| 08/486,069   | 06/07/1995  | DEAN ENGELHARDT      | ENZ-5(D8)(C2        | 6278             |
| 28171  | 7590        | 11/21/2005           | EXAMINER            |                  |
| ENZO BIOCHEM, INC.<br>527 MADISON AVENUE (9TH FLOOR)<br>NEW YORK, NY 10022 |             |                      | BRUSCA, JOHN S      |                  |
|  |             |                      | ART UNIT            | PAPER NUMBER     |

1631

DATE MAILED: 11/21/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

|   |                                      |  |  |
|---|--------------------------------------|--|--|
| <b>Examiner-Initiated Interview Summary</b> | <b>Application No.</b><br>08/486,069 | <b>Applicant(s)</b><br>ENGELHARDT ET AL. |  |
|   | <b>Examiner</b><br>John S. Brusca    | <b>Art Unit</b><br>1631                  |  |

**All Participants:**
**Status of Application:** 140

 (1) John S. Brusca.

(3) \_\_\_\_\_.

 (2) Ron Fedus.

(4) \_\_\_\_\_.

**Date of Interview:** \_\_\_\_

**Time:** \_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

 Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

none

Claims discussed:

1703, 1784

Prior art documents discussed:

none


**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
 (Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The applicants were requested to determine the most recent amendment to the claim for priority, and the most recent amendment to the abstract. The applicants stated they would respond with the paper dates of the most recent claim for priority and abstract amendment. The applicants were requested to correct antecedent basis for "said metal or metal ion" in claim 1703, and to point to written description support for claim 1784 drawn to a nuclease assay. The applicants were informed that no rejections for double patenting were contemplated in the instant application. .